Mabwell Secures NMPA Approval for Novel AML/MM Bispecific Antibody

Event summary

  • Mabwell received IND acceptance from the NMPA for its LILRB4/CD3 TCE bispecific antibody, 6MW5311, targeting AML, CMML, and MM.
  • 6MW5311 is the first TCE bispecific antibody to reach this stage of development for these hematologic malignancies.
  • Mabwell plans to submit a U.S. IND application to the FDA in Q2 2026.
  • Preclinical data demonstrates potent cytotoxic activity and a favorable safety profile in vitro and in vivo.

The big picture

Mabwell’s IND acceptance represents a significant advancement in the application of T Cell Engagers (TCEs) to hematologic malignancies, a space largely dominated by chemotherapy and targeted therapies. The company’s unique ‘2+1’ asymmetric molecular structure and steric hindrance design aim to improve safety and efficacy, potentially disrupting the current treatment paradigm. While TCEs have seen success in lymphoma, their application to AML, CMML, and MM presents a substantial market opportunity, but also carries significant clinical and regulatory hurdles.

What we're watching

Regulatory Risk
The FDA review process will be critical; delays or rejection could significantly impact Mabwell's valuation and future development plans, given the first-in-class nature of the asset.
Clinical Efficacy
The success of early-phase clinical trials will determine the long-term viability of 6MW5311, particularly given the high unmet need and competitive landscape in AML and MM.
Market Adoption
The adoption rate of TCE technology in AML and CMML will depend on demonstrating superior efficacy and safety compared to existing treatments, which primarily rely on chemotherapy and targeted therapies.

Related topics

CAGR